和黄医药（中国）有限公司（股票代码：00013）于2026年2月2日披露截至2026年1月31日的股份变动月报表。公告显示，公司注册股本维持在15亿股，面值每股0.1美元，总额1.5亿美元；本月无新增发行或注销行为，注册股本保持不变。
公司已发行股本方面，截至1月末，普通股总数维持在872,327,620股，未设库藏股。本月内未发生购回或发行股份事项，公司确认符合香港联交所上市规则的最低公众持股量要求。
股份期权方面，公司自2015年4月24日通过的认股权计划在报告期内有27,300份期权失效，期末持有期权总数为25,646,933份。本月并无因行使期权增发新股，亦无来自期权行使的资金流入。
综合以上，和黄医药（中国）有限公司于1月期间股本结构保持稳定，无新增发行或回购注销活动。报告由公司非执行董事兼公司秘书施熙德签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.